• 1
    Giustarini D, Dalle-Donne I, Tsikas D, Rossi R. Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers. Crit Rev Clin Lab Sci 2009;46:241281.
  • 2
    de Vries DK, Kortekaas KA, Tsikas D, Wijermars LG, van Noorden CJ, Suchy MT, et al. Oxidative damage in clinical ischemia/reperfusion injury: a reappraisal. Antioxid Redox Signal 2013;19:535545.
  • 3
    Becker T, Mevius I, de Vries DK, Schaapherder AF, zu Vilsendorf AM, Klempnauer J, et al. The l-arginine/NO pathway in end-stage liver disease and during orthotopic liver and kidney transplantation: biological and analytical ramifications. Nitric Oxide 2009;20:6167.
  • 4
    Tsikas D, Schwedhelm E, Stutzer FK, Gutzki FM, Rode I, Mehls C, Frölich JC. Accurate quantification of basal plasma levels of 3-nitrotyrosine and 3-nitrotyrosinoalbumin by gas chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003;784:7790.
  • 5
    Tsikas D, Duncan MW. Mass spectrometry and 3-nitrotyrosine: strategies, controversies, and our current perspective. Mass Spectrom Rev; doi:10.1002/mas.21396.
  • 6
    Tsikas D, Rode I, Becker T, Nashan B, Klempnauer J, Frölich JC. Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2α in end-stage liver disease. Hepatology 2003;38:10631064.